Targeting menin for precision therapy in high-risk acute myeloid leukemia

被引：0
|
作者：
Jamil, Abdur [1 ]
Qureshi, Zaheer [2 ]
El-amir, Zain Mary [3 ]
Kupakuwana-Suk, Gillian [4 ]
Akram, Hamzah [5 ]
Ahmad, Mohsin [6 ]
Huselton, Eric [7 ]
机构：
[1] Samaritan Med Ctr, Dept Med, Watertown, NY 13601 USA
[2] Quinnipiac Univ, Frank H Netter MD Sch Med, Bridgeport, CT USA
[3] Univ Michigan, Ann Arbor, MI USA
[4] Univ Ottawa, Ottawa Hosp, Leukemia Fellowship Program, Dept Med,Div Hematol, Ottawa, ON, Canada
[5] Hamilton Hlth Sci, Hamilton, ON, Canada
[6] CHRISTUS Southeast Texas St Elizabeth Hosp, Beaumont, TX USA
[7] Univ Rochester, Dept Hematol Oncol, Rochester, NY USA
来源：
LEUKEMIA RESEARCH REPORTS | 2025年 / 23卷
关键词：
Acute myeloid leukemia; Revumenib; KMT2A; Menin inhibition therapy; INHIBITOR; REVUMENIB;
D O I：
10.1016/j.lrr.2024.100495
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways. Summary: The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Evolving treatment strategies in patients with high-risk acute myeloid leukemia
    Schiller, Gary J.
    LEUKEMIA & LYMPHOMA, 2014, 55 (11) : 2438 - 2448
  • [22] Code status transitions in patients with high-risk acute myeloid leukemia
    Abrams, Hannah R.
    Nipp, Ryan D.
    Traeger, Lara
    Lavoie, Mitchell W.
    Reynolds, Matthew J.
    Ufere, Nneka N.
    Wang, Annie C.
    Boateng, Kofi
    LeBlanc, Thomas W.
    El-Jawahri, Areej
    BLOOD ADVANCES, 2022, 6 (14) : 4208 - 4215
  • [23] The "ultimate" haploidentical transplantation for the elderly with high-risk acute myeloid leukemia
    Pierini, Antonio
    Ruggeri, Loredana
    Carotti, Alessandra
    Falzetti, Franca
    Piccinelli, Sara
    Saldi, Simonetta
    Lancellotta, Valentina
    Aristei, Cynthia
    Velardi, Andrea
    Martelli, Massimo Fabrizio
    BONE MARROW TRANSPLANTATION, 2019, 54 (Suppl 2) : 803 - 805
  • [24] Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome
    Shadman, Mazyar
    Mawad, Raya
    Dean, Carol
    Chen, Tara L.
    Shannon-Dorcy, Kathleen
    Sandhu, Vicky
    Hendrie, Paul C.
    Scott, Bart L.
    Walter, Rol B.
    Becker, Pamela S.
    Pagel, John M.
    Estey, Elihu H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (06) : 483 - 486
  • [25] Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Shadman, Mazyar
    Mawad, Raya
    Dean, Carol
    Shannon-Dorcy, Kathleen
    Sandhu, Vicky
    Hendrie, Paul C.
    Scott, Bart L.
    Walter, Roland B.
    Becker, Pamela S.
    Pagel, John
    Estey, Elihu H.
    BLOOD, 2014, 124 (21)
  • [26] Targeting oxidative stress in high-risk pediatric acute lymphoblastic leukemia
    Mannan, Abdul
    Germon, Zacary P.
    Sillar, Jonathan
    Duchatel, Ryan J.
    Douglas, Alicia
    McCarthy, Kristy
    Alvaro, Frank
    Chamberlain, Janis
    Dun, Matthew D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 30 - 30
  • [27] High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).
    Larson, Sarah
    Campbell, Nicholas
    Huo, Dezheng
    Artz, Andrew
    Zhang, Yanming
    Gajria, Devika
    Green, Margaret
    Rahimova, Gamar
    Weiner, Howard
    Torres, Monica
    Odenike, Olatoyosi
    Godley, Lucy A.
    Rich, Elizabeth Shima
    Thirman, Michael
    Larson, Richard A.
    Stock, Wendy
    BLOOD, 2009, 114 (22) : 434 - 434
  • [28] Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia
    Lamble, Adam J.
    Ries, Rhonda E.
    Alonzo, Todd A.
    Wang, Yi-Cheng
    Farrar, Jason E.
    Huang, Benjamin J.
    Kutny, Matthew A.
    Pollard, Jessica A.
    Aplenc, Richard
    Gamis, Alan S.
    Kolb, Edward A.
    Cooper, Todd M.
    Meshinchi, Soheil
    BLOOD, 2022, 140 : 3393 - 3394
  • [29] Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia
    VeltriVeltri, Lauren
    Rezvani, Katayoun
    Oran, Betul
    Mehta, Rohtesh
    Rondon, Gabriela
    Kebriaei, Partow
    Popat, Uday
    Nieto, Yago
    Hosing, Chitra
    Qazilbash, Muzaffar
    Khouri, Issa
    Shpall, Elizabeth
    Champlin, Richard
    Marin, David
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03) : 505 - 514
  • [30] Uncommon cytogenetic abnormalities identifying high-risk acute myeloid leukemia in children
    Masetti, Riccardo
    Bertuccio, Salvatore Nicola
    Guidi, Vanessa
    Cerasi, Sara
    Lonetti, Annalisa
    Pession, Andrea
    FUTURE ONCOLOGY, 2020, 16 (33) : 2747 - 2762
12345